Fig_1.tif (325.63 kB)
Overview of human plasmas and animal sera.
figure
posted on 2015-05-29, 03:58 authored by Ema T. Crooks, Tommy Tong, Bimal Chakrabarti, Kristin Narayan, Ivelin S. Georgiev, Sergey Menis, Xiaoxing Huang, Daniel Kulp, Keiko Osawa, Janelle Muranaka, Guillaume Stewart-Jones, Joanne Destefano, Sijy O’Dell, Celia LaBranche, James E. Robinson, David C. Montefiori, Krisha McKee, Sean X. Du, Nicole Doria-Rose, Peter D. Kwong, John R. Mascola, Ping Zhu, William R. Schief, Richard T. Wyatt, Robert G. Whalen, James M. BinleyOur plasma and serum panel consisted of human plasmas from 4 HIV-1-infected donors and one uninfected donor, a pool of rabbit sera generated against monomeric JR-FL gp120, groups of rabbit and guinea pig sera generated to various JR-FL Env-VLP-based immunogens. Group 5 animals all received JR-FL-based immunogens via different DNA prime-protein boost protocols. The absolute dose of gp120 and gp140 immunogens is shown. VLP doses are given in estimated gp120 equivalents [28]. Adjuvants and immunization routes are shown (abbreviations are: IM intramuscular, SC subcutaneous and ID intradermal).
History
Usage metrics
Categories
Keywords
nAb titersbioinformatics analysisCD 4 Binding Site ElicitingNeutralizing Antibodies Bindglycan defensesclade B tier 2DNA trimer sera8 rabbitstier 2 phenotypepglimits access3 seraancvaccine researchresidue 197CD 4 binding sitefuture developmenttier 2 breadth20 rabbitsN 197 glycanglycan fenceneutralizing seraEnv trimerhivneutralizing antibody vaccinequaternary epitopestrimer VLP seratier 2 neutralizing antibodiesneutralizing DNA trimer serumdata show
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC